Brain imaging technology company EMVision has named Liverpool Hospital in NSW and Royal Melbourne Hospital in Victoria as the first two sites as part of a planned multi-site clinical trial this quarter.
The ASX-listed company, which is commercialising imaging techniques pioneered at University of Queensland for early stroke detection, announced in-principle agreements with the two hospitals on Tuesday. Liverpool would be the first site activated under the trial, followed by Royal Melbourne, with other sites named progressively, the company said.
CEO Dr Ron Weinberger added that EMVision was “pleased with the progress being made” and that it looked forward “to collaborating with our study sites as we move into the clinical trials.
“This is a key milestone in the development of our novel portable brain scanner as we seek to fulfil our mission of improving stroke patient outcomes.”
Weinberger’s company also said it had made a submission to the Human Research Ethics Committee, that its devices are in the advanced stage of commissioning, and that the studies would be supported by clinical research organisation Avania.
Avania is described in the statement as an international full-service contract research organisation focussed on management of clinical studies, supporting products from the first-in-human phase through to the post-market phase.
Initial clinical trials were announced in early 2020.
EMVision – which held its IPO in 2018 – is currently developing a first-generation scanner for bedside use in emergency departments and other clinical settings, in parallel with a second-generation version designed for first responders.
The second-generation product is currently the subject of a five-year project in partnership with the Australian Stroke Alliance, which has been awarded $8 million in funding from the Australian government’s Medical Research Future Fund.
Subscribe to our free @AuManufacturing newsletter here.